- Martyn Coombs - Chief Executive Officer
- Ian Wilson - Chief Operating Officer
- Matt De Luna - Chief Financial Officer
- William Le - Senior Director, Clinical Development
- Deepak Behera, MD - Senior Director Medical Affairs
- Jean Gudas, PhD - Consultant
- Ron Korn, MD, PhD - Consultant
- Andrew Dorr, MD - Consultant
- Robert E. Reiter, MD - Consultant
- Brian Abeysekera, PhD - Consultant
- Ivan Plavec, PhD - Consultant
- Alex Gibson, PhD - Consultant
- Jerry Liebrand - Consultant
- Thomas Digby - Consultant
Chief Executive Officer
Mr. Coombs is a recognized Industry Leader in Nuclear Medicine and Imaging. Most recently, as President of Jubilant DraxImage, he led the company through a period of rapid organic growth, tripling revenue in four years. He built a strong team, and advanced the development pipeline towards approval, specifically for Ruby-Fill®, a key PET Cardiology product. Mr. Coombs has held senior leadership roles at Amersham (now GE Healthcare), and Nihon Medi-Physics, where he was the number two Executive. Previously, he has served as CEO of Asterand PLC, a public life sciences company, where in 2008 he received an award from The Financial Times for the top performing stock on the London Stock Exchange, out of more than 2,000 companies. He has lived and worked in North America, Japan, and Europe. Mr. Coombs holds a degree in Mathematics, and an MBA with distinction from Warwick Business School.
Chief Operating Officer
Mr. Ian Wilson is the former CEO and CTO of Edinburgh Molecular Imaging Ltd, leading the development of novel optical imaging agents to improve cancer detection and surgery, and lung disease. He has held several roles at GE Healthcare between 1996 and 2013, including Portfolio and Strategy Manager and Head of Biology, with responsibility for management of GE Healthcare’s Molecular Imaging Agent Portfolio, in Cardiovascular, Oncology and Neurology, and strategic and tactical oversight. He had responsibility for supporting efficacy and regulatory studies required for the approval of new imaging agents. At Xstrahl Ltd, as CTO &COO, he was responsible for the oversight of the Radiotherapy commercial operation and manufacture oversight, including new product development. Mr. Wilson currently works and resides in the UK, though he travels extensively on behalf of ImaginAb. He is a graduate from University of Manchester with over 25 years’ experience in development of in vivo medical diagnostics and imaging medical devices.
Chief Financial Officer
Mr. De Luna has more than 15 years of progressive financial, corporate accounting, and operational leadership experience in industries spanning technology, real estate, energy, telecommunications, logistics / supply chain, manufacturing, and distribution. Prior to joining ImaginAb, he worked with TGG Accounting, a leading provider of outsourced accounting and business advisory services, as the firm’s Consulting CFO and Senior Controller for clients ranging from start-ups to entities with over 1,000 employees. Mr. De Luna positioned a rapidly growing, $430M public real estate company, The New Home Company, to complete a $47M follow-on equity offering and meet all SEC, GAAP, and SOX reporting requirements. At Edison Mission Energy, he guided the company through Chapter 11 bankruptcy proceedings to successful emergence after a $2.6B asset sale to NRG Energy. Earlier in his career as Acting CFO for a $90M Motorola subsidiary, Vertex Standard USA, Mr. De Luna returned the business to profitable operations, grew sales, eliminated financial misstatements, and facilitated a seamless integration with Motorola. Mr. De Luna’s credentials include a CPA, CGMA, and a Bachelor’s degree in Business Administration from California State University, Fullerton (CSUF).
Senior Director, Clinical Development
Mr. Le joined ImaginAb to lead the clinical development effort that includes Clinical Operations, Program and Project Management, and Strategic Alliance Management. Mr. Le has 14 years of industry experience in clinical research and cross-functional leadership in biotechnology and pharmaceutical drug development from Phase I–IV. Prior to joining ImaginAb, Mr. Le was the Senior Director of Clinical Operations at Gradalis Inc., a start-up biotechnology company developing personalized molecular-based immuno-oncology therapies, functioning in a similar leadership role and capacity. Prior to Gradalis, Mr. Le held various Clinical Operations leadership roles at Spectrum Pharmaceuticals where he managed and successfully completed two registration studies that were submitted for New Drug Application (NDA) review, resulting in one (Beleodaq®) being approved for the treatment of a rare cancer. Mr. Le obtained his Bachelor’s degree in Management from Oklahoma State University and his Master’s degree in Biotechnology Management from the University of Maryland University College.
Senior Director Medical Affairs
Dr. Behera is trained as a Nuclear Medicine physician with more than 15 years of broad range of experience across clinical work, academic research and pharmaceutical industry, with skills spanning medical affairs, preclinical to clinical translational research with PET tracers, and clinical imaging. Most recently, Dr. Behera was the Medical Director, Medical Affairs at Piramal Imaging, a radiopharmaceutical company, with a pipeline of tracers across Neurology, Cardiology and Oncology. Dr. Behera spent more than 10 years in clinical and pre-clinical molecular imaging research, during which he conceptually and operationally advanced imaging agents from preclinical stages to FDA submissions and early phase clinical trials (bench to bedside). At Stanford University, Dr. Behera served as an Institutional Official for regulatory compliance and finance for industry sponsored Clinical Trials and represented Stanford in liaisons with industry sponsors. Dr. Behera received his medical education in India and postdoctoral fellowship at Stanford University.
Dr. Gudas joined ImaginAb in August 2012 and brings broad experience in the research and development of monoclonal antibody and antibody drug conjugates to the position. She has an excellent working knowledge of the multiple facets of drug development from target discovery and validation, through lead candidate selection and optimization, preclinical efficacy, safety evaluation, IND submissions and translational biology. Prior to joining ImaginAb, she held the position of Senior Director of Preclinical Development at both Kite Pharma and Agensys/Astellas where she advanced a portfolio of novel, proprietary cancer targets and established a clinical pipeline of therapeutic human antibodies in multiple cancer indications. Her contributions have resulted in the progression of multiple antibody candidate therapeutics into clinical trials. Dr. Gudas received a dual degree in Microbiology and Chemistry from the University of Rhode Island, a Master’s degree in Microbiology and Immunology from the University of Oklahoma and a PhD degree from UCLA.
Dr. Korn is an internationally recognized expert in Cancer Imaging. A scientist at his core, he completed a PhD in Molecular Biology at Albert Einstein College of Medicine, his Medical Degree from Stanford School of Medicine and Residency and Fellowship training in Diagnostic Radiology and Nuclear Medicine from University of Pennsylvania. Dr. Korn has specialized in PET imaging, Radiopharmaceutical development and Cancer Biology for over 20 years with extensive involvement in clinical research leading to several high-profile publications in major peer review journals. His work has resulted in the approval of several cancer drugs based upon PET imaging. In addition, Dr Korn is a pioneer in the field of Radiomics which combines imaging with biologic processes for the development of non-invasive biomarkers. Along with his public recognition and awards from the American Society of Clinical Oncology, American College of Radiology Imaging Network, Ibis Foundation of Arizona and Radiology Society of North America he is the lead radiologist for the SU2C Pancreas Cancer Dream Team. He is currently the Founder and Chairman of Imaging Endpoints Research and Core Lab, an international core lab that oversees over 200 global trials. Dr Korn serves as a faculty member of Translational Genomics-City of Hope, ASU School of Medical Informatics and Virginia G Piper Cancer Center at HonorHealth in Scottsdale, Arizona. Dr Korn’s his passion for PET imaging and radiopharmaceutical development provides a foundation for clinical excellence, education and commitment to clinical research to help “connect imaging to the cure”.
Dr. Dorr is a medical oncologist with a long history of successful cancer drug development experience, with leadership participation in the development of Gemzar (gemcitabine) in pancreatic and non-small cell lung cancers, Treanda (bendamustine) in chronic lymphocytic leukemia and non-Hodgkin lymphoma as well as Avastin (bevacizumab) in glioblastoma. Dr. Dorr has had a successful consulting business in cancer drug development since 2005. Previously, he served as Chief Operating Officer at Salmedix Inc. from April 2003 until August 2004. From June 1996 to March 2003, he served as Vice President of oncology drug development at Isis (now Ionis) Pharmaceuticals, Inc. and served as its Chief Medical Officer. He also served as clinical research physician and then medical advisor at Eli Lilly & Company where he was responsible for the strategy for Lilly’s cancer pipeline from pre-clinical through Phase III development. While at the National Cancer Institute, he was responsible for national clinical trial programs in breast cancer, prostate, kidney, bladder and testicular cancers, as well as melanoma. Dr. Dorr has over 60 publications on drug development in books and journals.Dr. Dorr received his B.S. degree from Davidson College and holds his M.D. from the University of North Carolina at Chapel Hill.
Dr. Reiter is a Professor of Urology and Molecular Biology and Director of the Prostate Cancer Treatment and Research Program at the David Geffen School of Medicine at UCLA. He is currently the Principal Investigator of UCLA’s SPORE (Specialized Program in Research Excellence) program, a 12 million dollar research grant from the National Cancer Institute to develop new diagnostic and treatment options for men with prostate cancer. As co-developer of ImaginAb’s technology and Chief Medical Advisor, Dr. Reiter helps ensure high clinical impact and relevance by guiding the validation studies for ImaginAb’s clinical imaging pipeline. Dr. Reiter is a prominent figure in prostate cancer research and treatment, and is currently the Director of the Genitourinary Cancer Program in the Jonsson Comprehensive Cancer Center and the Director of Research in the Department of Urology at UCLA. Dr. Reiter completed his undergraduate studies at Yale University and medicine at Stanford University Medical School.
Dr. Brian Abeysekera, has more than 25 years of experience in radioisotope and radiopharmaceutical development, including production, radiochemistry, quality control, quality assurance and regulatory affairs activities in the United States and Canada. He is President of PharmaSPECT Inc, a company that provides cGMP and Manufacturing, Quality and Regulatory expertise to Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) radiopharmaceutical manufacturers. He previously served as Vice President, Manufacturing, Molecular Insight Pharmaceuticals where he was responsible for all aspects of supply chain management for the supply of drug products for clinical trials as well as commercial supply and for Contract Manufacturing contracts and services. From 1985 to 2007, he worked at MDS Nordion, where he held various positions, including Manager Radiopharmaceutical Development; Director, Quality Safety and Regulatory Affairs; and most recently, Director, Applied R&D. During his tenure at Nordion, Dr. Abeysekera helped establish the company as a cGMP supplier of sterile pharmaceuticals in the United States and Canada; designed, developed and validated aseptic manufacturing facilities; directed scale-up from clinical to commercial manufacturing; and developed chemistry and manufacturing sections for numerous small molecule and biologic products to support FDA submissions. Dr. Abeysekera holds a Ph.D. in synthetic organic chemistry from the University of British Columbia.
Dr. Ivan Plavec is a president and founder of Ascellna Life Science Group, a consulting firm supporting life science companies with innovative technologies and products. Ivan has over twenty-five years of experience in the biotechnology and pharmaceutical industry in business development and research, and has held senior research positions at Novartis and Systemix, and executive and business development positions at BioSeek and Asterand. He has negotiated and closed over one hundred deals including complex drug discovery collaborations, technology-based collaborations, and product and technology licensing deals. He is author on over thirty peer-reviewed publications, has filed numerous patents and has a strong track record of scientific accomplishments and broad scientific experience in systems biology, human primary cells, small molecule screening and optimization, drug repositioning, expression vectors, gene therapy, stem cells, retroviruses, immunology and oncology. He holds a Ph.D. in Molecular Biology from the University of Zürich, Switzerland.
Dr Alex Gibson has over 20 years’ of experience working in the Radiopharmaceutical industry primarily at GE Healthcare where he held several roles within R&D but most latterly as Head of Research Alliances. Within that position he had responsibility to build and maintain a wide variety of key partnerships. He has wide experience of creating innovative collaborative models with Pharma companies and academic institutions alike across a range of disease areas in different phases of research and development. Currently he works with several small diagnostic companies in developing and maintaining their key partnerships as they look to build their investigational assets towards market approval. Dr Gibson holds both BSc and PhD degrees in chemistry obtained at the University of Southampton.
We have retained the consulting services of Jerry Liebrand, Liebrand Consulting LLC to provide strategic direction for PSMA. Jerry served as Vice President, Product Acquisitions & Licensing for GE Healthcare. With more than 25 years in the healthcare industry, he has worked for leading companies including Sanofi Winthrop Pharmaceuticals, Nycomed AS, and Amersham plc.
Consultant, Global IP Asset Management
Thomas is a US/Canadian intellectual property (IP) and transaction attorney with 22+ years’ experience in Global IP Asset Management. He provides worldwide strategic advice for IP portfolio assets to achieve licensing, M&A and commercialization objectives. From 2005-2016, Thomas was a member of the legal/IP department at Novartis (Cambridge, MA and Basel, Switzerland).